Effective January 5, 2023, Leslie Sloan will no longer serve as Chief Operating Officer of Aeglea BioTherapeutics, Inc. Dr. Sloan's departure is not related to any legal, compliance or other matters of the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.58 USD | +6.18% |
|
+12.56% | +41.43% |
02:34pm | Evercore ISI Starts Spyre Therapeutics With Outperform Rating | MT |
07-01 | Spyre Therapeutics, Inc.(NasdaqGS:SYRE) added to Russell Small Cap Comp Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.43% | 1.46B | |
+20.31% | 127B | |
+24.21% | 117B | |
+25.44% | 27.67B | |
-18.48% | 20.33B | |
-15.17% | 16.79B | |
-15.91% | 15.63B | |
+12.84% | 14.84B | |
-47.10% | 14.65B | |
+57.15% | 14.43B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer